How I manage patients with inherited haemophilia A and B and factor inhibitors

Research output: Contribution to journalReview articlepeer-review


Development of inhibitors to coagulation factor VIII or IX is still the most challenging complication in haemophilia care. 'Bypassing agents' may be used to treat a bleed but the eradication of the inhibitor by immune tolerance induction (ITI) is the main objective in the treatment of a patient with haemophilia who has developed neutralizing antibodies. Several options exist for ITI and the patient may be at 'good' or 'bad risk' for successful outcome with different regimens. This paper offers a review of current regimens to be considered in the treatment of a bleed in a patient with an inhibitor but the main focus is the aspects of different choices in the management of the child or the adult with severe or mild forms of haemophilia A or B, who has developed an inhibitor. There are also some final outlooks on new and emerging treatment possibilities.

Original languageEnglish
Pages (from-to)501-510
JournalBritish Journal of Haematology
Issue number4
Early online date2017
Publication statusPublished - 2018 Feb

Subject classification (UKÄ)

  • Hematology

Free keywords

  • Factor IX
  • Factor VIII
  • Haemophilia
  • Immune tolerance induction
  • Inhibitors


Dive into the research topics of 'How I manage patients with inherited haemophilia A and B and factor inhibitors'. Together they form a unique fingerprint.

Cite this